Loading clinical trials...
Loading clinical trials...
A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis
Conditions
Interventions
GAD-alum
Placebo
Locations
1
Norway
Endokrinologisk poliklinikk, Oslo Universitetssykehus Aker
Oslo, Norway
Start Date
January 1, 2011
Primary Completion Date
January 1, 2013
Completion Date
January 1, 2013
Last Updated
May 17, 2018
NCT04638647
NCT07011147
NCT04119713
NCT05894746
NCT04521790
NCT06591260
Lead Sponsor
Oslo University Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions